Insider Selling: GRAIL (NASDAQ:GRAL) Insider Sells $1,152,528.47 in Stock

GRAIL, Inc. (NASDAQ:GRAL) insider Andrew Partridge sold 7,873 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $146.39, for a total value of $1,152,528.47. Following the completion of the sale, the insider directly owned 155,865 shares of the company’s stock, valued at approximately $22,817,077.35. The trade was a 4.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

GRAIL Stock Performance

GRAL traded down $4.38 during trading on Wednesday, reaching $132.90. 992,328 shares of the stock were exchanged, compared to its average volume of 980,656. The stock has a market cap of $5.94 billion, a P/E ratio of -13.63 and a beta of 2.83. GRAIL, Inc. has a twelve month low of $41.50 and a twelve month high of $166.48. The stock’s 50 day moving average price is $88.31 and its two-hundred day moving average price is $70.39.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The firm had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. Equities research analysts predict that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

GRAL has been the subject of a number of research analyst reports. TD Cowen reiterated a “buy” rating on shares of GRAIL in a report on Thursday, September 24th. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a research report on Sunday, September 13th. UBS Group lifted their target price on GRAIL from $105.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Mizuho boosted their target price on GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a report on Friday, September 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $102.70.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Moody National Bank Trust Division lifted its position in GRAIL by 1.3% during the third quarter. Moody National Bank Trust Division now owns 13,478 shares of the company’s stock worth $1,889,000 after acquiring an additional 178 shares during the last quarter. State Street Corp grew its position in shares of GRAIL by 26.1% in the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock valued at $162,859,000 after purchasing an additional 493,621 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of GRAIL by 26.3% in the second quarter. The Manufacturers Life Insurance Company now owns 21,597 shares of the company’s stock valued at $1,474,000 after purchasing an additional 4,498 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of GRAIL during the second quarter worth approximately $82,000. Finally, Arizona State Retirement System lifted its holdings in GRAIL by 8.6% during the 2nd quarter. Arizona State Retirement System now owns 10,470 shares of the company’s stock worth $715,000 after purchasing an additional 833 shares during the last quarter.

GRAIL Company Profile

GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.